Last reviewed · How we verify
gefitinib combined with chemotherapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
gefitinib combined with chemotherapy (gefitinib combined with chemotherapy) — Qilu Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| gefitinib combined with chemotherapy TARGET | gefitinib combined with chemotherapy | Qilu Pharmaceutical Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- gefitinib combined with chemotherapy CI watch — RSS
- gefitinib combined with chemotherapy CI watch — Atom
- gefitinib combined with chemotherapy CI watch — JSON
- gefitinib combined with chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). gefitinib combined with chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/gefitinib-combined-with-chemotherapy. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab